Raymond James & Associates 9 Meters Biopharma, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 25, 2022
BUY
$0.21 - $0.32 $16,800 - $25,600
80,000 Added 441.99%
98,100 $21,000
Q2 2022

Aug 12, 2022
BUY
$0.26 - $0.64 $1,326 - $3,264
5,100 Added 39.23%
18,100 $5,000
Q4 2020

Feb 12, 2021
BUY
$0.65 - $1.11 $812 - $1,387
1,250 Added 10.64%
13,000 $11,000
Q3 2020

Nov 04, 2020
BUY
$0.48 - $0.84 $5,640 - $9,870
11,750 New
11,750 $10,000

Others Institutions Holding NMTR

# of Institutions
3
Shares Held
67.9K
Call Options Held
0
Put Options Held
0
View Full List

About 9 METERS BIOPHARMA, INC.

NMTR Quotes by TradingView
  • Ticker NMTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,955,400
  • Market Cap $259K
  • Description
  • 9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...
More about NMTR
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email